RTP Mobile Logo
Select Publications

Aalders KC et al. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. Eur J Cancer 2017;79:98-105. Abstract

Albain KS et al. Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11(1):55-65. Abstract

Andre  F et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO Clinical Practice Guideline update — Integration of results from TAILORx. J Clin Oncol 2019;37(22):1956-64. Abstract

Cardoso F et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375(8):717-29. Abstract

Cardoso F, Curigliano G. The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “type” or to “print”? NPJ Breast Cancer 2018;4:12. Abstract

Dinan MA et al. Chemotherapy costs and 21-gene Recurrence Score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2005 to 2011. J Natl Compr Canc Netw 2019;17(3):245-54. Abstract

Ding S et al. Evaluation of the incorporation of Recurrence Score into the American Joint Committee on Cancer eighth edition staging system in patients with T1-2N0M0, estrogen receptor-positive, human epidermal growth receptor 2-negative invasive breast cancer: A population-based analysis. Oncologist 2019;[Epub ahead of print]. Abstract

Gluz O et al. West German Study Group phase III PlanB trial: First prospective outcome data for the 21-gene Recurrence Score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016;34(20):2341-9. Abstract

Francis PA et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379(2):122-37. Abstract

Henry NL et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: Update of the ASCO endorsement of the Cancer Care Ontario guideline. J Clin Oncol 2019;37(22):1965-77. Abstract

Hochheiser L et al. Multi-gene assays: Effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. J Comp Eff Res 2019;8(5):289-304. Abstract

Krop I et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2017;35(24):2838-47. Abstract

Lange S et al. Interpretation of the results of the MINDACT study and consequent recommendations in the updated ASCO Clinical Practice Guideline. J Clin Oncol 2018;36(4):429-30. Abstract

Mamounas EP et al. 21-gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: Results from NSABP B-28/NRG Oncology. Breast Cancer Res Treat 2018;168(1):69-77. Abstract

Mariotto A et al. Expected monetary impact of Oncotype DX score-concordant systemic breast cancer therapy based on the TAILORx trial. J Natl Cancer Inst 2019;[Epub ahead of print]. Abstract

Nitz U et al. West German Study PlanB trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019;37(10):799-808. Abstract

Nitz U et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: Five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 2017;165(3):573-83. Abstract

Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract

Sparano JA et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019;380(25):2395-405. Abstract

Sparano JA et al. Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene Recurrence Score (RS) in TAILORx. ASCO 2019;Abstract 503.

Sparano JA et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379(2):111-21. Abstract

Sparano JA. Gene expression assays in early-stage breast cancer. Oncology (Williston Park) 2018;32(10):510-2. Abstract

Sparano JA. Prognostic gene expression assays in breast cancer: Are two better than one? NPJ Breast Cancer 2018;4:11. Abstract

Sparano JA, Gray R. TAILORx: Questions answered, lessons learned, and remaining knowledge gaps. J Clin Oncol 2019;37(21):1841-2. Abstract

Varga Z et al. Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer. Int J Cancer 2019;145(4):882-93. Abstract

Wagner LI et al. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results. San Antonio Breast Cancer Symposium 2018;Abstract GS6-03.

Wang SY et al. Incorporating tumor characteristics to maximize 21-gene assay utility: A cost-effectiveness analysis. J Natl Compr Canc Netw 2019;17(1):39-46. Abstract

Wolmark N et al. Prognostic impact of the combination of Recurrence Score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: Results from NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. J Clin Oncol 2016;34(20):2350-8. Abstract